New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
August 5, 2014
07:43 EDTAEZSAeterna Zentaris signs co-promotion services agreement with ASCEND Therapeutics
Aeterna Zentaris announced a strategic co-promotion services agreement with ASCEND Therapeutics US. Under the terms of the agreement, expected to start in the Q4, Aeterna Zentaris will use its newly established commercial structure to market, in specific U.S. territories, ASCEND's EstroGel a non-patch transdermal, FDA approved and commercialized estrogen replacement therapy. For its part, ASCEND would market, in specific U.S. territories, MacrilenTM, Aeterna Zentaris' product for use in the evaluation of adult growth-hormone deficiency for which a New Drug Application is currently under review by the FDA, with a Prescription Drug User Fee Act date of November 5. In consideration for these co-promotion services, each party will be entitled to receive, from the other party, commissions on net sales of each other's product.
News For AEZS From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
November 20, 2014
07:34 EDTAEZSAeterna Zentaris adds center to Phase 3 trial in endometrial cancer
Aeterna Zentaris announced the opening of a new clinical site at the Hollings Cancer Center of the Medical University of South Carolina in Charleston, South Carolina, for the company's ongoing multinational, pivotal ZoptEC Phase 3 trial in women with advanced, recurrent or metastatic endometrial cancer. Furthermore, the company announced that patient recruitment for this trial now stands at over 320 patients out of a projected total of 500 patients. Patient recruitment is in line to secure expected interim analysis in H1 2015, the company said.

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use